-1-

SEQUENCE LISTING

	<110>	NeuTec Pharma PLC	
5		BURNIE, James P	
		MATTHEWS, Ruth C	
	<120>	Treatment of Infection due to Clostridium difficile	•
10	<130>	MP100397-WO	
	<150>	GB0306782.4	
	<151>	2003-03-25	
15	<160>	7	
	<170>	PatentIn version 3.2	
	<210>	1	
20	<211>	975	
	<212>	DNA	
	<213>	Clostridium difficile	
25	<220>		
	<221>	CDS	
	<222>	(40)(975)	
	<400>	1	
30			
		taa taatttaata attacaggag ggtattgat atg aaa ata cta gta	54
		Met Lys Ile Leu Val 1 5	
		1 5	
	ttt gga	gca cgc gat tat gaa gaa cca gta ata aaa aaa tgg tct gaa	102
35		Ala Arg Asp Tyr Glu Glu Pro Val Ile Lys Lys Trp Ser Glu	102
		10 15 20	
	<i>C</i> 22 <i>C</i> 25		
	gaa cat	aag gat gtt caa gtg gat att tat cct gaa aac atg act gaa	150
	GTU UTB	Lys Asp Val Gln Val Asp Ile Tyr Pro Glu Asn Met Thr Glu	

-2-

					25					3	0						35					
5	G)	ia ai .u Ai	sn 7	gta Val 40	gti Val	t aa l Ly	a go	et aa .a Ly	aa gg 7s G: 45	ly I	at	gat Asp	Gl Gl	t at	le S	ct er	at.	a ca e Gl	aa Ln	caa Gln	19	8
10	ac Th	t aa r As 55	n]	at 'yr	ata	ı gai	t aa o As	t cc n Pr 60	о Ту	at a	tt le '	tat Tyr	ga: Gl:	a ac u Th 65	r L	ta eu	aaa Lys	a ga s As	ıt P	gct Ala	24	6
	99 G1 70	g gt y Va	t a l L	ıaa ıys	gtt Val	ata Ile	gc Ala 75	t tca	a ag r Ar	a ao	et g	gca Ala	80 GJ ⁷ 333	g gt 7 Va	t ga	ac sp	atg Met	at : Il	e :	cat His 85	294	1
15	Phe	t ga e As	t t p L	ta eu	gtt Val	aat Asn 90	gaa Glu	a aat 1 Asr	gg Gl	a ct y Le	u I	le 5	gtt Val	aca Thi	a aa r As	ac g	gtt Val	Pro	o 2	gct Ala	342	!
20	tat Tyr	tca Se	a co	ro I	aat Asn 105	gca Ala	ata Ile	gct Ala	gaa Glu	a tt 1 Le 11	u A	ct la	gtt Val	act Thr	ca Gl	n A	gct Ala 115	atg Met	g a	ac Asn	390	
25	ctt Leu	tta Leu	a ag ı Ar 12	gI	ys aag	act Thr	cct Pro	cta Leu	gta Val	Ly:	ga sL:	aa a ys]	aaa Lys	gtc Val	tg Cy:	s G	gaa Slu	ggt Gly	9 A	at .sp	438	
30	tac Tyr	cgt Arg 135	Tr	p I	ata :le .	gct Ala	gaa Glu	ctt Leu 140	ctt Leu	GJ ⁷	a ac	ca g	gaa Blu	gtt Val 145	aga Arg	a t	ct er	att Ile	a T	ca hr	486	
	gtt Val 150	ggt Gly	gt Va	t a l I	ta (Зlу	aca Thr 155	gga Gly	aaa Lys	ata	G1	у А	ıct la .60	act Thr	tct Ser	: g	ca la :	aaa Lys	Le	ta eu 55	534	
35	ttc Phe	aaa Lys	G1 ⁷	A P	eu (gga Sly 2 .70	gct Ala	aat Asn	gta Val	att Ile	gc Al 17	a T	at g	gac Asp	caa Gln	ta Ty	r l	cca Pro	aa As	it sn	582	
	agt	gat	tta	a aa	ac g	at a	ata	tta	act	tac	aa	a ga	at t	tet	tta	ga	a g	jac	ct	t	630	

- 3 -

	Ser Asp Leu Asn Asp Ile Leu Thr Tyr Lys Asp Ser Leu Glu Asp Leu 185 190 195	
5	cta aaa gaa gct gac gtt ata aca tta cat act cct tta ctt gaa gga Leu Lys Glu Ala Asp Val Ile Thr Leu His Thr Pro Leu Leu Glu Gly 200 205 210	678
10	aca aaa cat atg ata aat aaa gat act cta gct ata atg aag gat gga Thr Lys His Met Ile Asn Lys Asp Thr Leu Ala Ile Met Lys Asp Gly 215 220 225	726
15	gct tac ata gta aat act gcc cgt ggt ggt tta att gat aca ggg gat Ala Tyr Ile Val Asn Thr Ala Arg Gly Gly Leu Ile Asp Thr Gly Asp 230 235 240 245	774
	tta ata gaa gca cta gac tca gga aaa att aga gct gct gcc ctt gat Leu Ile Glu Ala Leu Asp Ser Gly Lys Ile Arg Ala Ala Ala Leu Asp 250 255 260	822
20	aca ttt gaa act gaa gga ttg ttc tta aac aaa aaa atg aat cct gga Thr Phe Glu Thr Glu Gly Leu Phe Leu Asn Lys Lys Met Asn Pro Gly 265 270 275	870
25	gaa tta act gac cca gaa ata aat aaa ctt ctt tct atg gaa caa gtt Glu Leu Thr Asp Pro Glu Ile Asn Lys Leu Leu Ser Met Glu Gln Val 280 285 290	918
30	ata ttc act cat cat ctt ggt ttc ttc act agt aca gcg att gaa aat Ile Phe Thr His His Leu Gly Phe Phe Thr Ser Thr Ala Ile Glu Asn 295 300 305	966
35	ata gtt taa Ile Val 310	975
	<210> 2 <211> 311 <212> PRT	

WO 2004/085637 PCT/GB2004/001383

-4-

<213> Clostridium difficile

<400> 2

5 Met Lys Ile Leu Val Phe Gly Ala Arg Asp Tyr Glu Glu Pro Val Ile 1 5 10 15

Lys Lys Trp Ser Glu Glu His Lys Asp Val Gln Val Asp Ile Tyr Pro
20 25 30

10

Glu Asn Met Thr Glu Glu Asn Val Val Lys Ala Lys Gly Tyr Asp Gly
35 40 45

Ile Ser Ile Gln Gln Thr Asn Tyr Ile Asp Asn Pro Tyr Ile Tyr Glu

50 55 60

Thr Leu Lys Asp Ala Gly Val Lys Val Ile Ala Ser Arg Thr Ala Gly
65 70 75 80

20 Val Asp Met Ile His Phe Asp Leu Val Asn Glu Asn Gly Leu Ile Val 85 90 95

Thr Asn Val Pro Ala Tyr Ser Pro Asn Ala Ile Ala Glu Leu Ala Val 100 105 110

25

Thr Gln Ala Met Asn Leu Leu Arg Lys Thr Pro Leu Val Lys Lys Lys 115 120 125

Val Cys Glu Gly Asp Tyr Arg Trp Ile Ala Glu Leu Leu Gly Thr Glu

130 135 140

Val Arg Ser Ile Thr Val Gly Val Ile Gly Thr Gly Lys Ile Gly Ala 145 150 155 160

35 Thr Ser Ala Lys Leu Phe Lys Gly Leu Gly Ala Asn Val Ile Ala Tyr 165 170 175

Asp Gln Tyr Pro Asn Ser Asp Leu Asn Asp Ile Leu Thr Tyr Lys Asp 180 185 190

WO 2004/085637 PCT/GB2004/001383

-5-

Ser Leu Glu Asp Leu Leu Lys Glu Ala Asp Val Ile Thr Leu His Thr

Fro Leu Leu Glu Gly Thr Lys His Met Ile Asn Lys Asp Thr Leu Ala 210 215 220

Ile Met Lys Asp Gly Ala Tyr Ile Val Asn Thr Ala Arg Gly Gly Leu
225 230 235 240

10

Ile Asp Thr Gly Asp Leu Ile Glu Ala Leu Asp Ser Gly Lys Ile Arg
245 250 255

Ala Ala Ala Leu Asp Thr Phe Glu Thr Glu Gly Leu Phe Leu Asn Lys

260 265 270

Lys Met Asn Pro Gly Glu Leu Thr Asp Pro Glu Ile Asn Lys Leu Leu 275 280 285

20 Ser Met Glu Gln Val Ile Phe Thr His His Leu Gly Phe Phe Thr Ser 290 295 300

Thr Ala Ile Glu Asn Ile Val 305 310

25

<210> 3

<211> 20

<212> DNA

30 <213> Artificial Sequence

<220>

<223> PCR primer.

35 <400> 3

atgaaaatac tagtatttgg

-6-

<211> 21 <212> DNA <213> Artificial Sequence 5 <220> <223> PCR primer <400> 4 ttaaactata ttttcaatcg c 10 <210> 5 <211> 17 <212> DNA 15 <213> Artificial sequence <220> <223> PCR Primer 20 <400> 5 gttttcccag tcacgac <210> 6 25 <211> 17 <212> DNA <213> Artificial sequence <220> 30 <223> PCR Primer <400> 6 caggaaacag ctatgac 35 <210> 7 <211> 20 <212> DNA <213> Artificial sequence

21 17 17

WO 2004/085637

- 7 -

<220>

<223> PCR Primer

<400> 7

5 atgccatagc atttttatcc

20